PDF herunterladen
CC BY 4.0 · Thromb Haemost
DOI: 10.1055/a-2595-1927
Stroke, Systemic or Venous Thromboembolism

Serum MPO-DNA for Predicting the Risk of Venous Thromboembolism and the Effect of Statins in Patients with Spontaneous Intracerebral Hemorrhage

Xinyan Yan
1   Department of Neurology, Hunan Provincial People's Hospital and The First-Affiliated Hospital of Hunan Normal University, Changsha, Hunan, People's Republic of China
,
Wenyan Huang
2   Department of Pulmonary and Critical Care Medicine, Hunan Provincial People's Hospital and The First-Affiliated Hospital of Hunan Normal University, Changsha, Hunan, People's Republic of China
,
Yunrong Chen 
2   Department of Pulmonary and Critical Care Medicine, Hunan Provincial People's Hospital and The First-Affiliated Hospital of Hunan Normal University, Changsha, Hunan, People's Republic of China
› Institutsangaben Funding This work was supported by the Scientific Research Plan Project of the Health Commission of Hunan Province (202203023609, 202214015252) and the General Program of the Hunan Provincial Natural Science Foundation of China (2025JJ50671).
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints


Abstract

Background

Patients with spontaneous intracerebral hemorrhage (ICH) are at high risk of venous thromboembolism (VTE). Recent studies have shown the involvement of neutrophil extracellular traps (NETs) in thrombogenesis.

Objectives

To explore the predictive value of serum MPO-DNA (a NETs surrogate) for VTE and the effect of statins on serum MPO-DNA levels and the VTE incidence in ICH patients.

Methods

This prospective cohort study enrolled 117 ICH patients and 15 healthy controls. Serum MPO-DNA levels were measured via ELISA. The relationship between serum MPO-DNA levels and VTE risk was analyzed. The predictive value of MPO-DNA was evaluated by ROC curves. Effects of statin on NETs and VTE incidence were evaluated.

Results

The median MPO-DNA level in patients with VTE was 0.304 (95% CI: 0.231–0.349), significantly higher than the 0.188 (95% CI: 0.159–0.236) in non-VTE patients. Elevated MPO-DNA levels were associated with an increased VTE risk (OR 7.13, 95% CI 2.58–19.75; P < 0.001), and this association persisted after adjustment. The AUC values for MPO-DNA, CRP, and D-dimer were 0.824 (95% CI: 0.719–0.928), 0.618 (95% CI: 0.481–0.754), and 0.786 (95% CI: 0.683–0.888), respectively. Moreover, statin users exhibited reduced MPO-DNA levels (0.174 vs. 0.218; P = 0.007), though VTE incidence differences (13.8% vs. 19.3%) lacked statistical significance.

Conclusion

Serum MPO-DNA serves as a sensitive biomarker for VTE prediction in ICH, highlighting NETs as potential therapeutic targets. Statins could attenuate NETosis, but larger trials are required to validate their clinical efficacy and safety in VTE prevention for ICH patients.

Keywords

cerebral hemorrhage - neutrophil extracellular traps - MPO-DNA - venous thromboembolism - hydroxymethylglutaryl-CoA reductase inhibitors

Data Availability Statement

The data that support the findings of this study are available on reasonable request from the corresponding author.




Publikationsverlauf

Eingereicht: 08. März 2025

Angenommen: 23. April 2025

Accepted Manuscript online:
28. April 2025

Artikel online veröffentlicht:
09. Mai 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9 (02) 167-176
    CrossrefPubMedSuche in Google Scholar
  • 2 Jolink WM, Klijn CJ, Brouwers PJ, Kappelle LJ, Vaartjes I. Time trends in incidence, case fatality, and mortality of intracerebral hemorrhage. Neurology 2015; 85 (15) 1318-1324
    CrossrefPubMedSuche in Google Scholar
  • 3 Cordonnier C, Demchuk A, Ziai W, Anderson CS. Intracerebral haemorrhage: current approaches to acute management. Lancet 2018; 392 (10154): 1257-1268
    CrossrefPubMedSuche in Google Scholar
  • 4 Greenberg SM, Ziai WC, Cordonnier C. et al; American Heart Association/American Stroke Association. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke 2022; 53 (07) e282-e361
    CrossrefPubMedSuche in Google Scholar
  • 5 Stecker M, Michel K, Antaky K, Cherian S, Koyfmann F. Risk factors for DVT/PE in patients with stroke and intracranial hemorrhage. Open Neurol J 2014; 8: 1-6
    PubMedSuche in Google Scholar
  • 6 Ji R, Li G, Zhang R, Hou H, Zhao X, Wang Y. Higher risk of deep vein thrombosis after hemorrhagic stroke than after acute ischemic stroke. J Vasc Nurs 2019; 37 (01) 18-27
    PubMedSuche in Google Scholar
  • 7 Cai Q, Zhang X, Chen H. Patients with venous thromboembolism after spontaneous intracerebral hemorrhage: a review. Thromb J 2021; 19 (01) 93
    CrossrefPubMedSuche in Google Scholar
  • 8 Ding D, Sekar P, Moomaw CJ. et al. Venous thromboembolism in patients with spontaneous intracerebral hemorrhage: a multicenter study. Neurosurgery 2019; 84 (06) E304-E310
    PubMedSuche in Google Scholar
  • 9 Paciaroni M, Agnelli G, Venti M, Alberti A, Acciarresi M, Caso V. Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies. J Thromb Haemost 2011; 9 (05) 893-898
    CrossrefPubMedSuche in Google Scholar
  • 10 Yao M, Ma J, Wu D. et al. Neutrophil extracellular traps mediate deep vein thrombosis: from mechanism to therapy. Front Immunol 2023; 14: 1198952
    PubMedSuche in Google Scholar
  • 11 Guy A, Favre S, Labrouche-Colomer S. et al. High circulating levels of MPO-DNA are associated with thrombosis in patients with MPN. Leukemia 2019; 33 (10) 2544-2548
    PubMedSuche in Google Scholar
  • 12 Al-Ghoul WM, Kim MS, Fazal N, Azim AC, Ali A. Evidence for simvastatin anti-inflammatory actions based on quantitative analyses of NETosis and other inflammation/oxidation markers. Results Immunol 2014; 4: 14-22
    PubMedSuche in Google Scholar
  • 13 Chen YR, Xiang XD, Sun F. et al. Simvastatin reduces NETosis to attenuate severe asthma by inhibiting PAD4 expression. Oxid Med Cell Longev 2023; 2023: 1493684
    PubMedSuche in Google Scholar
  • 14 Stępień K, Natorska J, Ząbczyk M, Zalewski J, Jawień J, Undas A. High-dose atorvastatin and rosuvastatin reduce the levels of neutrophil extracellular trap-related proteins in coronary artery disease: association with prothrombotic state. Pol Arch Intern Med 2024; 134 (10) 16852
    PubMedSuche in Google Scholar
  • 15 Yang L, Liu Q, Zhang X. et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. Nature 2020; 583 (7814) 133-138
    PubMedSuche in Google Scholar
  • 16 Lacut K, Bressollette L, Le Gal G. et al; VICTORIAh (Venous Intermittent Compression and Thrombosis Occurrence Related to Intra-cerebral Acute hemorrhage) Investigators. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology 2005; 65 (06) 865-869
    PubMedSuche in Google Scholar
  • 17 Paciaroni M, Agnelli G, Alberti A. et al. PREvention of VENous Thromboembolism in Hemorrhagic Stroke Patients - PREVENTIHS Study: a randomized controlled trial and a systematic review and meta-analysis. Eur Neurol 2020; 83 (06) 566-575
    PubMedSuche in Google Scholar
  • 18 Diaz JA, Fuchs TA, Jackson TO. et al; for the Michigan Research Venous Group*. Plasma DNA is elevated in patients with deep vein thrombosis. J Vasc Surg Venous Lymphat Disord 2013; 1 (04) 341-348.e1
    CrossrefPubMedSuche in Google Scholar
  • 19 Rosell A, Gautam G, Wannberg F. et al. Neutrophil extracellular trap formation is an independent risk factor for occult cancer in patients presenting with venous thromboembolism. J Thromb Haemost 2023; 21 (11) 3166-3174
    PubMedSuche in Google Scholar
  • 20 Nordenholz KE, Mitchell AM, Kline JA. Direct comparison of the diagnostic accuracy of fifty protein biological markers of pulmonary embolism for use in the emergency department. Acad Emerg Med 2008; 15 (09) 795-799
    PubMedSuche in Google Scholar
  • 21 Smith P, Rosell A, Farm M. et al. Markers of neutrophil activation and neutrophil extracellular traps in diagnosing patients with acute venous thromboembolism: a feasibility study based on two VTE cohorts. PLoS One 2022; 17 (07) e0270865
    PubMedSuche in Google Scholar
  • 22 Li W, Wang Z, Su C. et al. The effect of neutrophil extracellular traps in venous thrombosis. Thromb J 2023; 21 (01) 67
    PubMedSuche in Google Scholar
  • 23 Martinod K, Demers M, Fuchs TA. et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A 2013; 110 (21) 8674-8679
    CrossrefPubMedSuche in Google Scholar
  • 24 Perdomo J, Leung HHL, Ahmadi Z. et al. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat Commun 2019; 10 (01) 1322
    CrossrefPubMedSuche in Google Scholar
  • 25 Hisada Y, Grover SP, Maqsood A. et al. Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors. Haematologica 2020; 105 (01) 218-225
    CrossrefPubMedSuche in Google Scholar
  • 26 Brill A, Fuchs TA, Savchenko AS. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10 (01) 136-144
    CrossrefPubMedSuche in Google Scholar
  • 27 von Brühl ML, Stark K, Steinhart A. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209 (04) 819-835
    CrossrefPubMedSuche in Google Scholar
  • 28 Várady CBS, Oliveira AC, Monteiro RQ, Gomes T. Recombinant human DNase I for the treatment of cancer-associated thrombosis: a pre-clinical study. Thromb Res 2021; 203: 131-137
    CrossrefPubMedSuche in Google Scholar
  • 29 Glynn RJ, Danielson E, Fonseca FA. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360 (18) 1851-1861
    CrossrefPubMedSuche in Google Scholar
  • 30 Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol 2017; 4 (02) e83-e93
    PubMedSuche in Google Scholar
  • 31 Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. Eur Heart J 2017; 38 (20) 1608-1612
    PubMedSuche in Google Scholar
  • 32 Davis JW, Weller SC, Porterfield L, Chen L, Wilkinson GS. Statin use and the risk of venous thromboembolism in women taking hormone therapy. JAMA Netw Open 2023; 6 (12) e2348213
    PubMedSuche in Google Scholar
  • 33 Farmakis IT, Christodoulou KC, Hobohm L, Konstantinides SV, Valerio L. Lipid lowering for prevention of venous thromboembolism: a network meta-analysis. Eur Heart J 2024; 45 (35) 3219-3227
    CrossrefPubMedSuche in Google Scholar
  • 34 Goldstein MR, Mascitelli L, Pezzetta F. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2009; 72 (16) 1448 , author reply 1448–1449
    PubMedSuche in Google Scholar
  • 35 Katsanos AH, Lioutas VA, Charidimou A. et al; International META-MICROBLEEDS Initiative. Statin treatment and cerebral microbleeds: a systematic review and meta-analysis. J Neurol Sci 2021; 420: 117224
    PubMedSuche in Google Scholar
  • 36 McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012; 43 (08) 2149-2156
    PubMedSuche in Google Scholar
  • 37 Pezzini A, Tarantino B, Zedde ML. et al; Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy) Investigators. Statin use and long-term risk of recurrent intracerebral haemorrhage: the MUCH-Italy. J Neurol Neurosurg Psychiatry 2024; 96 (01) 95-99
    PubMedSuche in Google Scholar
  • 38 Gaist D, García Rodríguez LA, Hallas J. et al. Association of statin use with risk of stroke recurrence after intracerebral hemorrhage. Neurology 2023; 101 (18) e1793-e1806
    PubMedSuche in Google Scholar
  • 39 Flint AC, Conell C, Rao VA. et al. Effect of statin use during hospitalization for intracerebral hemorrhage on mortality and discharge disposition. JAMA Neurol 2014; 71 (11) 1364-1371
    PubMedSuche in Google Scholar
  • 40 Blanco M, Nombela F, Castellanos M. et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69 (09) 904-910
    PubMedSuche in Google Scholar
  • 41 Li B, Li G, Yang X, Song Z, Wang Y, Zhang Z. NETosis in psoriatic arthritis: serum MPO-DNA complex level correlates with its disease activity. Front Immunol 2022; 13: 911347
    PubMedSuche in Google Scholar